What amount sold does BIOZONE PHARMACEUTICALS, INC. report in Form D filings?

The latest linked filings report $28.9M sold across 17 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was BIOZONE PHARMACEUTICALS, INC.'s most recent SEC filing?

BIOZONE PHARMACEUTICALS, INC.'s most recent Form D filing was on 2017-05-02.

How many investors does BIOZONE PHARMACEUTICALS, INC. have?

The most recent Form D filing lists 3 investor(s).

What type of securities does BIOZONE PHARMACEUTICALS, INC. offer?

BIOZONE PHARMACEUTICALS, INC.'s SEC Form D filings indicate equity offerings.

BIOZONE PHARMACEUTICALS, INC.

CIK: 0001412486·Pharmaceuticals·TUCKER, GA·Corporation

Reported Sold

$28,917,571

Total Filings

Identified Offerings

Last Filed

May 2, 2017

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

May 2, 2017Form D — New notice

Reported sold: $3,000,000 · Target: $3,000,000

Rule 506(b)·3 investors

Sep 15, 2016Form D — New notice

Reported sold: $4,008,201 · Target: $4,008,201

Rule 506(b)·4 investors

Mar 30, 2016Form D — New notice

Reported sold: $5,004,370 · Target: $5,004,370

Rule 506(b)·12 investors

Jan 31, 2014Form D — New notice

Reported sold: $2,750,000 · Target: $2,750,000

Rule 506(b)·8 investors

Jan 17, 2014Form D — New notice

Reported sold: $0 · Target: $0

Rule 506(b)·23 investors

Nov 5, 2013Form D — New notice

Reported sold: $3,500,000 · Target: $3,500,000

Rule 506(b)·22 investors

Sep 5, 2013Form D — New notice

Reported sold: $2,000,000 · Target: $2,000,000

Rule 506·1 investor

Apr 22, 2013Form D — New notice

Reported sold: $800,000 · Target: Indefinite

Rule 506·5 investors

Jun 25, 2012Form D — New notice

Reported sold: $200,000 · Target: $200,000

Rule 506·2 investors

May 29, 2012Form D — New notice

Reported sold: $250,000 · Target: $250,000

Rule 506·1 investor

Apr 26, 2012Form D — New notice

Reported sold: $2,250,000 · Target: $2,250,000

Rule 506·10 investors

Apr 25, 2012Form D — New notice

Reported sold: $500,000 · Target: $500,000

Rule 506·1 investor

Apr 25, 2012Form D — New notice

Reported sold: $455,000 · Target: $455,000

Rule 506·5 investors

Apr 25, 2012Form D — New notice

Reported sold: $250,000 · Target: $250,000

Rule 506·1 investor

Mar 20, 2012Form D — New notice

Reported sold: $1,000,000 · Target: $1,000,000

Rule 506·1 investor

Mar 9, 2012Form D — New notice

Reported sold: $2,300,000 · Target: $2,300,000

Rule 506·3 investors

Jan 26, 2012Form D — New notice

Reported sold: $650,000 · Target: $650,000

Rule 506·3 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$231,500

Amendment Rate

Latest reported sold across 17 identified offerings

$28,917,571

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Elliot M. Maza

Related Person

Appears on 9 filings

Christian Oertle

Related Person

Appears on 8 filings

Roberto Prego-Novo

Related Person

Appears on 8 filings

Brian Keller

Related Person

Appears on 8 filings

Phillip Frost

Related Person

Appears on 4 filings

Sam Lee

Related Person

Appears on 3 filings

Jane H. Hsiao

Related Person

Appears on 3 filings

Steven D. Rubin

Related Person

Appears on 3 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
May 2, 2017	New	$3,000,000	$3,000,000	3
Sep 15, 2016	New	$4,008,201	$4,008,201	4
Mar 30, 2016	New	$5,004,370	$5,004,370	12
Jan 31, 2014	New	$2,750,000	$2,750,000	8
Jan 17, 2014	New	$0	$0	23
Nov 5, 2013	New	$3,500,000	$3,500,000	22
Sep 5, 2013	New	$2,000,000	$2,000,000	1
Apr 22, 2013	New	Indefinite	$800,000	5
Jun 25, 2012	New	$200,000	$200,000	2
May 29, 2012	New	$250,000	$250,000	1
Apr 26, 2012	New	$2,250,000	$2,250,000	10
Apr 25, 2012	New	$500,000	$500,000	1
Apr 25, 2012	New	$455,000	$455,000	5
Apr 25, 2012	New	$250,000	$250,000	1
Mar 20, 2012	New	$1,000,000	$1,000,000	1
Mar 9, 2012	New	$2,300,000	$2,300,000	3
Jan 26, 2012	New	$650,000	$650,000	3

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Telemachus Therapeutics, Inc.

Pharmaceuticals

Offering target: $1,500,000

Filed Oct 28, 2026